Table 4.
Landmark analysis of MACEs in whole and nondiabetic patients.
| Variable | Hazard ratio (95% CI) | SEM | P value |
|---|---|---|---|
| Whole (≤32 months) | |||
| MCV-L | Reference | ||
| MCV-Mb | 1.359 (0.536-3.447) | 0.478 | 0.518 |
| MCV-Hb | 2.979 (1.331-6.671) | 0.411 | 0.020 |
| Whole (>32 months to maximum follow-up) | |||
| MCV-L | Reference | ||
| MCV-Mb | 0.933 (0.447-1.945) | 0.375 | 0.852 |
| MCV-Hb | 1.410 (0.675-2.948) | 0.376 | 0.361 |
| Non-DM (≤32 months) | |||
| MCV-L | Reference | ||
| MCV-Mb | 1.400 (0.334-5.864) | 0.731 | 0.645 |
| MCV-Hb | 4.054 (1.192-13.789) | 0.625 | 0.025 |
| Non-DM (>32 months to maximum follow-up) | |||
| MCV-L | Reference | ||
| MCV-Mb | 1.119 (0.420-2.985) | 0.501 | 0.822 |
| MCV-Hb | 1.596 (0.647-3.936) | 0.461 | 0.310 |
ACS: acute coronary syndrome; MACEs: major adverse cardiovascular events; MCV: mean corpuscular volume; CI: confidence interval; SEM: standard error of measurement. bCompared with MCV-L group.